Neu2000 is a new drug candidate for the treatment of stroke, spinal cord injury, and Acute Myocardiac Infarction; it has both antioxidant and NMDA antagonist effects. Neu2000 has completed phase I clinical trial for stroke in US.

GNT Pharma is now aiming to prepare phase 2 clinical testing.